GATINEAU, QC, Aug. 28 /CNW Telbec/ - ImaSight Corp. (IAS:TSX-V) announced
today its eight month interim results for the period ending June 30, 2008.
ImaSight recorded sales of $574,387, a gross profit of $237,297 and a
comprehensive and net loss of $1,029,950. Detailed interim statements are
available at www.sedar.com.
ImaSight also announced that it has appointed Apexx Equipment, Inc. of
Englewood, Colorado and CAN-med Healthcare (Health Imaging Division) of
Mississauga, Ontario as distributors of its ImaSight 4600 digital x-ray
sensor. Both companies provide professional services to retrofit the ImaSight
sensor into existing x-ray systems and to provide the sensor as the digital
imaging technology for new equipment.
Apexx Equipment integrates the ImaSight 4600 with its ClearVet digital
x-ray system which is marketed both directly and through Professional
Veterinary Products, Ltd. (PVPL). PVPL is owned by over 2,400 practicing
veterinarians and has annual sales of about $350 million to veterinary clinics
across the United States. Under a long-term agreement with PVPL, Apexx
Equipment acts as its Equipment Division.
CAN-med Healthcare, a division of the IMP Group of Halifax, NS, is a
leading national based, health imaging equipment and accessory provider in
ImaSight further announces the sale of a second sensor to a
100+ veterinary hospital chain through another North American distributor, AFP
Imaging of New York, which integrates the ImaSight 4600 sensor into their
Digital VetTek x-ray system. This sale follows a three month evaluation period
of their first sensor purchase with the goal of converting the entire chain to
"Our new partners have developed a strong market reputation for product
sales and service," said John Brooks CEO of ImaSight. "With more industry
leaders such as PVPL, Apexx and CAN-med choosing to exclusively promote our
digital sensor we anticipate positive sales moving forward."
ImaSight markets its patented digital x-ray sensor at a price affordable
to veterinarians and chiropractors. Its hospital grade sensor has been
approved for sale by Health Canada. Its Liponex division is developing natural
source products for the treatment of cholesterol. Further information can be
found at www.imasight.com
Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause ImaSight's actual results, performance or achievements
to be materially different from those expressed or implied by any of the
Company's statements. Actual events or results may differ materially. We
disclaim any intention and assume no obligation to update these
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: John Brooks, CEO, (819) 777-7979, ext. 223,